Zhaoke Ophthalmology Limited
Research Zhaoke Ophthalmology Limited (9FX) on Bullrun: market cap EUR 138.95M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker9FX
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 138.95M
- Financial periodFY2025
- RevenueCNY 31.97M
- Revenue growth-53.9%
- Net income-CNY 208.98M
- Free cash flow-CNY 265.04M
- Gross margin50.2%
Valuation Snapshot
latest market cap is EUR 138.95M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 31.97M | -CNY 208.98M | -CNY 265.04M | 50.2% | -0.38 | CNY 959.31M | CNY 292.36M | CNY 1.58B |
| FY2024 | CNY 69.32M | -CNY 237.49M | -CNY 297.79M | 74.7% | -0.43 | CNY 1.12B | CNY 238.59M | CNY 1.90B |
| FY2023 | CNY 18.75M | -CNY 385.04M | -CNY 418.93M | 76.0% | -0.71 | CNY 1.46B | CNY 238.03M | CNY 2.05B |
| FY2022 | CNY 0 | -CNY 407.32M | -CNY 569.60M | n/a | -0.75 | CNY 1.72B | CNY 131.93M | CNY 2.35B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 138.95M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Zhaoke Ophthalmology Limited
Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zhaoke Ophthalmology Limited's market cap?
Zhaoke Ophthalmology Limited's market capitalization is EUR 138.95M.
What does Zhaoke Ophthalmology Limited do?
Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis.